Valuation: Sumitomo Pharma Co., Ltd.

Capitalization 645B 4.02B 3.49B 3.19B 3.01B 5.6B 382B 5.71B 37.74B 14.77B 185B 15.1B 14.77B P/E ratio 2026
7.72x
P/E ratio 2027 * 6.99x
Enterprise value 798B 4.98B 4.32B 3.95B 3.73B 6.93B 473B 7.06B 46.72B 18.28B 229B 18.69B 18.29B EV / Sales 2026
2.2x
EV / Sales 2027 * 1.28x
Free-Float
51.03%
Yield 2026 *
-
Yield 2027 * 1.41%
1 day+1.59%
1 week-11.46%
Current month-11.46%
1 month-16.91%
3 months-22.11%
6 months-41.13%
Current year-38.01%
1 week 1,414.5
Extreme 1414.5
1,638
1 month 1,414.5
Extreme 1414.5
1,803.5
Current year 1,414.5
Extreme 1414.5
3,288
1 year 786
Extreme 786
3,288
3 years 279
Extreme 279
3,288
5 years 279
Extreme 279
3,288
10 years 279
Extreme 279
4,135
Manager TitleAgeSince
Chief Executive Officer 65 2024-06-24
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 2022-03-31
Director TitleAgeSince
Director/Board Member 64 2025-06-24
Director/Board Member 65 2016-05-31
Director/Board Member 62 2018-05-31
Change 5d. change 1-year change 3-years change Capi.($)
+1.59%-11.46%+75.89%+121.76% 4.02B
+0.55%+2.39%+47.77%+154.68% 1,009B
+2.02%+3.30%+51.48%+47.03% 560B
+1.02%+4.37%+21.21%+66.03% 401B
+0.77%-0.67%+22.19%+12.23% 328B
+2.24%+0.41%+29.51%+17.50% 288B
+1.85%+0.14%+22.04%+30.54% 272B
+4.43%-3.11%-40.46%-47.48% 194B
+1.15%+3.80%+21.76%+57.55% 189B
-0.02%-3.92%+16.93%+66.19% 160B
Average +1.56%-0.12%+26.83%+52.60% 340.55B
Weighted average by Cap. +1.34%+1.93%+31.30%+70.18%

Financials

2026 2027 *
Net sales 441B 2.75B 2.39B 2.18B 2.06B 3.83B 261B 3.9B 25.8B 10.1B 127B 10.32B 10.1B 545B 3.4B 2.95B 2.7B 2.55B 4.73B 323B 4.82B 31.9B 12.49B 157B 12.77B 12.49B
Net income 99.3B 619M 538M 492M 464M 863M 58.82B 879M 5.81B 2.27B 28.52B 2.33B 2.28B 88.95B 555M 482M 441M 416M 773M 52.69B 787M 5.21B 2.04B 25.55B 2.08B 2.04B
Net Debt 153B 957M 831M 760M 718M 1.33B 90.92B 1.36B 8.98B 3.52B 44.09B 3.59B 3.52B 55.61B 347M 301M 276M 260M 483M 32.94B 492M 3.26B 1.27B 15.97B 1.3B 1.27B
Logo Sumitomo Pharma Co., Ltd.
Sumitomo Pharma Co Ltd is a Japan-based company mainly engaged in the pharmaceutical business. The Company operates through three geographical segments. The Japan segment is engaged in the manufacture, purchase, and sale of prescription drugs, purchase and sale of medical devices, undertakes development and manufacture in the field of regenerative medicine and cellular medicine, and the manufacture of pharmaceuticals, medical devices, and regenerative medicine products that have been developed through joint development in the field of regenerative medicine. This segment also provides storage and delivery service of pharmaceuticals. The North America segment is engaged in the manufacture, purchase, and sale of prescription drugs. The Asia segment is engaged in the manufacture and sale of prescription drugs (small packaging), and the import, purchase and sale of prescription drugs in Southeast Asia and Taiwan, as well as the provision and collection of information on products.
Employees
3,832
Date Price Change Volume
26-06-05 1,437.00 ¥ +1.59% 4,200,400
26-06-04 1,414.50 ¥ -3.02% 4,881,600
26-06-03 1,458.50 ¥ -2.38% 4,915,400
26-06-02 1,494.00 ¥ -4.45% 5,789,600
26-06-01 1,563.50 ¥ -3.67% 4,578,800
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
1,437.00JPY
Average target price
2,073.57JPY
Spread / Average Target
+44.30%

Quarterly revenue - Rate of surprise